The study will also evaluate the safety and tolerability of the tracer, gather pharmacokinetic and metabolic data, and assess PET imaging parameters and image quality. LMI1195 is Lantheus' second product using molecular imaging and PET technology for cardiovascular imaging to enter clinical development from its research pipeline, according to the company.
Lantheus signs Australian moly deal, June 15, 2009
PETNet signs supply deal with Lantheus, June 11, 2009
Lantheus completes Definity study enrollment, May 28, 2009
Lantheus signs Mo-99 supply deal, May 20, 2009
Moly crisis leads to price hike for Lantheus technetium generators, May 15, 2009
Copyright © 2009 AuntMinnie.com
If you like this content, please share it with a colleague!